AUCTORES
Globalize your Research
Short Review | DOI: https://doi.org/10.31579/2640-1053/051
1 Department of Internal Medicine, University of California Davis, USA
*Corresponding Author: Edward J. Kim, UC Davis Comprehensive Cancer Center, Sacramento, CA 95817 USA.
Citation: Jasmine C. Huynh, Justin A. Chen, Mili Arora, May Cho, Edward J. Kim. Strategic Combinations of Aurora Kinase an Inhibiton with Targeted Drugs for Synergistic Anti-Tumor Effect, J. Cancer Research and Celllular Therapeutics . Doi:10.31579/2640-1053/051
Copyright: © 2019 Edward J. Kim, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,provided the original author and source are credited.
Received: 25 May 2019 | Accepted: 06 June 2019 | Published: 07 June 2019
Keywords: aurora kinase A; mitotic inhibitor; cell cycle; tumorigenesis
Inhibition of mitosis is an established therapeutic approach in the treatment of cancer. However, existing drugs that use this mechanism including taxanes cause off-target effects leading to dose-limiting toxicity such as sensory neuropathy. Development of inhibitors of mitosis-specific targets has created the next generation of mitosis inhibitors with the goal of achieving similar anti-tumor efficacy but with less toxicity. Aurora Kinase A is one example of a mitosis-specific target for which multiple drugs have been developed as anti-cancer therapy. Although early preclinical studies have showed on-target effects, clinical development has been slowed by minimal efficacy as monotherapy. However, strategic combinations of Aurora Kinase A inhibition with various targeted drugs has shown promise and led to renewed interest in the potential of inhibiting this mitosis-specific target.
The Aurora Kinase family is comprised of three members; Aurora Kinase A (AKA), Aurora Kinase B (AKB) and Aurora Kinase C (AKC). Aurora Kinases are serine/threonine kinases that regulate chromosomal segregation during mitosis and meiosis. AKA and AKB are expressed in most cell types whereas AKC is only expressed in the testis. AKA controls premetaphase events, AKB is crucial for precise chromosome segregation and cytokinesis, and AKC and controls spermatogenesis [1-3]. Though all members of the Aurora Kinase family have oncogenic properties, AKA was the first family member to be identified as one of the main kinases that regulates cell proliferation and for this reason, is an attractive drug target1. This review focuses on AKA as a potential target for next-generation mitotic inhibition, especially in combination with other targeted agents.
AKA plays a crucial role in centrosome maturation, mitotic entry, G2/M transition, spindle assembly and cytokinesis [2,4,5]. In normal cells, AKA induces phosphorylation of TACC, leading to complex formation with XMAP215 to promote centrosomal microtubule stabilization [2,6,7]. Prior to M phase, AKA couples with Bora to induce phosphorylation and activation of PLK. Activated PLK1 then activates CDK1/cyclin B via degradation of Wee1, a CDK-inhibitory kinase, and activation of CDK-promoting phosphatase CDC25C. Simultaneously, AKA activates CDC25B, another CDK-activator. This series of events further enhances the G2/M transition2. AKA additionally phosphorylates Ajuba which is a LIM protein and this interaction forms a positive feedback loop to initiate mitosis. There is an additional positive feedback loop between AKA and TPX2, and deficiencies in either component leads to defective spindle formation2.
Role of AKA in tumorigenesis
AKA has several roles in tumorigenesis and has been associated with multiple cancers, including breast cancer, gliomas, lung cancer, head and neck carcinoma, gastric cancer, esophageal cancer, and hematologic malignancies. In general, cancer cells with AKA overexpression have amplified centrosomes and multipolar spindles, genomic instability due to failure to resolve cytokinesis, and aberrant activation of pro-oncogenic signaling pathways, such as the nuclear factor kB and B-catenin/WNT pathway [4,8,9]. AKA’s specific role in tumorigenesis has been investigated in multiple tumor types. AKA has been shown to prevent N-myc degradation in neuroblastoma10, promote epithelial-to-mesenchymal transition (EMT) in breast cancer cells11, and promote growth of KRAS-mutant lung and GI tumor cells potentially through phosphorylation of RPS6KB1 [8,12].
Targeting AKA for cancer therapy
Given AKA’s role in tumorigenesis, inhibition of AKA has been an attractive strategy based on its potential to provide a novel effective way to suppress cancer progression. Multiple AKA inhibitors have been developed, including MLN8237 (alisertib), MK5108 (VX-689), and MLN80541. Alisertib has progressed the furthest in clinical development among the AKA inhibitors and has been tested in multiple Phase I-II trials, with some Phase III trials emerging [13-18]. However, AKA inhibitors as monotherapy have consistently disappointed demonstrating minimal clinically meaningful efficacy. A phase III study of single-agent alisertib in relapsed/refractory peripheral T-cell lymphoma showed no improvement of progression-free survival or response rate compared to investigator’s choice, leading to early study termination18.
Combining inhibition of AKA with targeted drugs
This overall poor response of cancer cells to AKA inhibition alone has led to investigation of combination strategies anchored on AKA inhibition.
Wee1 inhibitor
In TP53-mutant HNSCC cells, the addition of adavosertib, a Wee1 inhibitor, to alisertib resulted in mitotic catastrophe-mediated cell death through highly abnormal mitoses with unaligned, dispersed chromosomes, disorganized multipolar spindles, and distorted and ballooned cellular morphology4. Cells treated with combination therapy also showed increased levels of cleaved-PARP, suggesting induction of apoptosis. These findings were confirmed in in vivo models where combination therapy dramatically decreased tumor growth and prolonged survival of mice compared to vehicle or single-agent therapy. Additionally, murine weight remained stable suggesting the combination was minimally toxic. Mechanistically, Wee1 is an inhibitor of CDK1; its addition promotes cell-cycle progression, mitotic entry, and transition through the G2/M-checkpoint in the presence of defective spindle assembly and failed centrosome maturation induced by AKA inhibition, thus resulting in mitotic catastrophe.
MEK inhibitor
MEK is part of the MAPK signaling pathway and affects cellular response to DNA damage [19,20]. This has led to the hypothesis that combining MEK inhibition with AKA inhibition may result in more robust cell death. MEK inhibition disrupts DNA repair and cell cycle progression in G1, thus addition of MEK inhibitors promotes genomic instability induced by AKA inhibition and facilitates sustained cell cycle arrest [19,21,22]. Furthermore, MEK inhibition can induce degradation of c-Myc which upregulates expression of AKA in hepatocellular carcinoma and B-cell lymphomas [19,23,24]. In BRAF-mutant melanoma cell lines, combination trametinib (MEK inhibitor) and MLN8054 had more pronounced anti-proliferative effects as compared to combination trametinib and dabrafenib, the latter of which is a now a first-line regimen in BRAF-mutated advanced melanomas[19,25]. In KRAS- and PIK3CA-mutant colorectal cancer cell models, combining alisertib with MEK inhibition led to a more robust anti-proliferative response19.
BH3 mimetic
The Bcl2 family of proteins include both pro- and anti-apoptotic members that share Bcl2 homology (BH) domains including BH3. BH3 mimetics such as ABT263 block select anti-apoptotic members of the Bcl2 family of proteins but fail to inhibit all, including MCL-126. This incomplete blockade is thought to be one potential pathway of resistance to BH3 mimetic monotherapy. MLN8237 induces mitotic arrest which leads to MCL-1 degradation, thus introducing a way to overcome this potential resistance mechanism. In four pancreatic cancer cell lines treated with monotherapy MLN8237 or ABT263, there was variable sensitivity to either single agent26. However, combination MLN8237 and ABT263 resulted in a synergistic increase of sensitivity in all four cell lines. In vivo testing of this combination on pancreatic cell xenografts and patient-derived pancreatic cancer organoids (PDO) showed greater tumor growth inhibition compared to either agent alone. Both pancreatic cancer cell lines and PDOs showed an increase in Caspase 3/7 activity, suggesting that an increase in apoptosis was responsible for the observed cell growth inhibition. Combining AKA inhibition with Bcl2 inhibition has also been tested in double hit lymphoma and has shown promise through arrest of cell cycle progression and promotion of apoptosis27.
EGFR inhibitor
EGFR inhibitors have become a standard treatment option for EGFR-mutated non-small cell lung cancers (NSCLC). However, inevitable development of resistance to EGFR inhibitors limits durability of response. One potential mechanism of EGFR inhibitor resistance is through an increase in expression of TPX2 which activates AKA and protects it from degradation28. Patient-derived NSCLC xenografts treated with combination rociletinib, a 3rd generation EGFR inhibitor, and MLN8237 led to stronger initial reduction in tumor growth as compared to single-agent rociletinib, which only partially abrogated tumor growth and led to rapid tumor progression. Similarly, the combination of osimertinib, another 3rd generation EGFR inhibitor, and MLN8237 resulted in decreased tumor growth in nine out of ten tested xenografts28. Combination treatment caused a decrease in ERK and NF-
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
